Eli Lilly says its weight loss drug Zepbound outperformed Wegovy in a study
Eli Lilly said its drug Zepbound led to greater weight reduction than rival Novo Nordisk's Wegovy in a head-to-head randomized controlled trial.
Lilly’s Zepbound beats Novo’s Wegovy in high-stakes obesity drug trial
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, a finding that could advantage Lilly in the companies’ market competition.
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a $100B market.
Why Amgen's MariTide could rival Eli Lilly, Novo Nordisk's obesity drugs
Unlike its rivals, which require weekly injections, MariTide offers the potential for monthly or less frequent dosing
Lilly's Zepbound tops Wegovy for weight loss in head-to-head trial
Eli Lilly said on Wednesday patients on obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in-demand rival medicines.
Eli Lilly’s stock rises after its Zepbound weight-loss drug achieved better results than rival Wegovy in a head-to-head trial
Eli Lilly & Co. Inc.’s stock rose 2% early Wednesday, after the company said a study comparing its Zepbound weight-loss drug to rival Novo Nordisk’s Wegovy showed an average weight loss of 20.2% of body weight compared with 13.
Lilly’s Zepbound Beats Novo’s Wegovy in First Head-to-Head Trial
Eli Lilly & Co. said its weight-loss drug Zepbound outperformed rival Novo Nordisk A/S’s Wegovy in the first head-to-head trial of the two blockbusters.
Eli Lilly’s Zepbound Beats Novo Nordisk’s Wegovy in First Head-to-Head Study
People who took Zepbound lost 17 pounds more on average after 72 weeks of treatment than those who were given Novo Nordisk’s drug.
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss Trial
Eli Lilly said Wednesday that its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in a head-to-head clinical trial.
Eli Lilly’s Zepbound outperforms Novo's Wegovy for weight loss in head-to-head trial
Eli Lilly's weight-loss drug Zepbound outperformed Novo Nordisk's Wegovy in a head-to-head trial, leading to a rise in Lilly's shares.
Altimmune CEO on what’s next for its experimental obesity drug
Vipin Garg, Altimmune CEO, joins 'Fast Money' to discuss Altimmune announcing topline results from its obesity drug trial, ...
What's Next for Amgen Obesity Drug After Investors Disappointed by Results
Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.
BioPharma Dive7d
Amgen obesity drug cuts weight in study, but results miss Wall Street’s high mark
Shares in Amgen fell by double digits Tuesday on results for the company’s MariTide shot, which is viewed as a potential ...
Novo Nordisk’s Wegovy launches in China, offering obesity drug at a fraction of US prices
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, ...
Amgen Obesity Drug More Effective Than Competitors
A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.
Biden administration proposes expanding obesity drug coverage under Medicare and Medicaid
The Biden administration has proposed a new rule to “significantly” expand coverage of anti-obesity medications for Americans ...
McKnight's Long-Term Care News7d
CMS’ obesity drug coverage implications for nursing home patients
A new rule proposed by CMS presents alterations to the Medicare program, including expanded coverage for anti-obesity ...
Tahlequah Daily Press18h
KAISER HEALTCH CARE: Who Gets Obesity Drugs Covered by Insurance? In North Carolina, It Helps If You’re on Medicaid
After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets ...
MarketWatch1d
Health Care Flat on Mixed Obesity-Drug Fortunes - Health Care Roundup
Recent data from an Amgen obesity-drug trial only reinforced investors' impressions that Eli Lilly and Novo Nordisk have a prohibitive head start, thanks, in particular, to a new generation of ...